Literature DB >> 14520710

Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer.

Yongde Liao1, Rainer Grobholz, Ulrich Abel, Lutz Trojan, Maurice Stephan Michel, Peter Angel, Doris Mayer.   

Abstract

AKT/PKB is a central signaling molecule related to stimulation of cell proliferation and inhibition of apoptosis. Perturbations of AKT expression and function play an important role in tumor development and progression. We wanted to determine (a) whether AKT is overexpressed in human prostatic tumors, (b) whether AKT expression is correlated with tumor grade, and (c) whether AKT expression correlates with clinicopathological parameters. AKT expression was investigated by immunohistochemistry in sections from 56 paraffin-embedded prostate specimens displaying benign prostatic tissue (BPT), prostatic intraepithelial neoplasia (PIN), and primary tumors graded 2-5 according to Gleason. The staining intensity for AKT was significantly more pronounced in tumors compared to BPT, with PIN ranging between BPT and carcinomas. Similarly, the fraction of AKT-positive cells was higher in tumors than in BPT. A score of AKT expression (calculated as product from intensity and fraction of positive cells) ranging from 0-6 was also significantly higher in tumors than in BPT. Furthermore, the intensity of AKT expression in tumors showed a positive correlation with high preoperative serum levels of prostate specific antigen (PSA >/= 10 ng/ml, p = 0.0325). These data show that AKT is upregulated in prostate cancer and that expression is correlated with tumor progression. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14520710     DOI: 10.1002/ijc.11471

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  39 in total

1.  Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells.

Authors:  Yewseok Suh; Farrukh Afaq; Naghma Khan; Jeremy J Johnson; Fatima H Khusro; Hasan Mukhtar
Journal:  Carcinogenesis       Date:  2010-06-08       Impact factor: 4.944

2.  Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-κB, and androgen receptor signaling.

Authors:  Gagan Deep; Subhash C Gangar; Nicholas H Oberlies; David J Kroll; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2010-10       Impact factor: 4.784

Review 3.  Lipid raft: A floating island of death or survival.

Authors:  Kimberly S George; Shiyong Wu
Journal:  Toxicol Appl Pharmacol       Date:  2012-01-24       Impact factor: 4.219

Review 4.  Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance.

Authors:  Shaun McKenzie; Natasha Kyprianou
Journal:  J Cell Biochem       Date:  2006-01-01       Impact factor: 4.429

5.  Wortmannin inhibits K562 leukemic cells by regulating PI3k/Akt channel in vitro.

Authors:  Qing Wu; Yan Chen; Guohui Cui; Yiquan Cheng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-08-07

Review 6.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

7.  Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.

Authors:  Z Wu; D Gioeli; M Conaway; M J Weber; D Theodorescu
Journal:  Prostate       Date:  2008-06-15       Impact factor: 4.104

8.  MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN.

Authors:  Zhang Chun-Zhi; Han Lei; Zhang An-Ling; Fu Yan-Chao; Yue Xiao; Wang Guang-Xiu; Jia Zhi-Fan; Pu Pei-Yu; Zhang Qing-Yu; Kang Chun-Sheng
Journal:  BMC Cancer       Date:  2010-07-12       Impact factor: 4.430

9.  Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies.

Authors:  Tina Dreher; Hanswalter Zentgraf; Ulrich Abel; Alexandra Kappeler; Maurice S Michel; Uwe Bleyl; Rainer Grobholz
Journal:  Virchows Arch       Date:  2004-04-29       Impact factor: 4.064

Review 10.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.